Acquisition

Servier
Pharma

Servier rounds out rare cancer offerings with $2.5B Day One buy

Servier has unveiled a deal to acquire commercial-stage Day One Biopharmaceuticals and its med Ojemda for $21.50 per share in cash.
Fraiser Kansteiner Mar 6, 2026 10:14am
more expensive
Favicon Fierce Biotech

China is no longer licensing 'bargain basement': analyst

Feb 24, 2026 5:07pm
MA
Favicon Fierce Biotech

4 trends driving biopharma M&A this year, per Bain

Jan 28, 2026 5:00pm
Maryland flag MD flag Maryland MD

Samsung Bio shells out $280M to secure first US production site

Dec 22, 2025 9:14am
A chessboard with blocks that read MA

BioMarin makes its largest transaction, paying $4.8B for Amicus

Dec 19, 2025 11:28am
tennis tennis ball tennis court ball in court ball in your court

With $2.37B offer, Alkermes sweetens deal to acquire Avadel

Nov 19, 2025 9:53am